Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization

被引:22
作者
Achour, Oussama [1 ]
Poupard, Nicolas [1 ]
Bridiau, Nicolas [1 ]
Juchereau, Stephanie Bordenave [1 ]
Sannier, Frederic [1 ]
Piot, Jean-Marie [1 ]
Arnaudin, Ingrid Fruitier [1 ]
Maugard, Thierry [1 ]
机构
[1] Univ La Rochelle, UMR CNRS 7266, LIENSS, Equipe Approches Mol Environm Sante,Dept Biotechn, F-17042 La Rochelle, France
关键词
Heparin; Ultrasonic-assisted radical hydrolysis; Heparinase I-catalyzed beta-elimination; Glycol-split; Heparanase; Anti-angiogenesis; GLYCOL-SPLIT HEPARINS; TUMOR ANGIOGENESIS; ANTICOAGULANT ACTIVITY; CANCER PROGRESSION; COAGULATION SYSTEM; ANTITHROMBIN; DEGRADATION; SULFATE; MECHANISM; THERAPY;
D O I
10.1016/j.carbpol.2015.08.041
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Heparanase is an endo-beta-D-glucuronidase that plays an important role in cancer progression, in particular during tumor angiogenesis and metastasis. Inhibiting this enzyme is considered as one of the most promising approaches in cancer therapy. Heparin is a complex glycoaminoglycan known as a strong inhibitor of heparanase. It is primarily used in clinical practice for its anticoagulant activities, which may not be compatible with its use as anti-angiogenic agent. In this study, we described the production of ultra-low-molecular-weight heparins (ULMWH) by a physicochemical method that consists in a hydrogen peroxide-catalyzed radical hydrolysis assisted by ultrasonic waves. We assessed the structural characteristics, anticoagulant and anti-heparanase activities of the obtained heparin derivatives and compared them with three commercial low-molecular-weight heparins (LMWH), glycol-split non-anticoagulant heparins and heparins produced by enzymatic methods. ULMWH generated by the physicochemical method were characterized by high anti-heparanase and moderate anticoagulant activities. These heparin derivatives might be potential candidates for cancer therapy when a compromise is needed between anti-heparanase and anticoagulant activities. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 50 条
  • [31] Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update
    Antonio Vitiello
    Francesco Ferrara
    [J]. Cardiovascular Drugs and Therapy, 2023, 37 : 277 - 281
  • [32] Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update
    Vitiello, Antonio
    Ferrara, Francesco
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (02) : 277 - 281
  • [33] Patients' Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
    Harenberg, Job
    Hetjens, Svetlana
    Weiss, Christel
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [34] Patients' Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
    Harenberg, Job
    Hetjens, Svetlana
    Weiss, Christel
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [35] Patients' Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
    Harenberg, Job
    Hetjens, Svetlana
    Weiss, Christel
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [36] Impact of exogenous antithrombin on low molecular weight heparin anti-Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels
    Schaefer, Beverly
    Hausfeld, Adriane
    Martin, Matthew
    Steele, Paul
    Martin, Jan
    Reher, Sandra R.
    Lane, Adam
    Luchtman-Jones, Lori
    [J]. PEDIATRIC BLOOD & CANCER, 2020, 67 (11)
  • [37] Low-Molecular-Weight Heparin and Anti-Xa Targets in Critically Ill Children: Are We on Target With Our Target?
    Parker, Robert I.
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2014, 15 (07) : 679 - 681
  • [38] Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
    Andrade, S. A.
    Carrijo-Carvalho, L. C.
    Peceguini, L. A. M.
    Wlian, L.
    Sato, A. C.
    Luchiari, C.
    Silva, E. D.
    Maffei, F. H. A.
    Chudzinski-Tavassi, A. M.
    [J]. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2012, 45 (10) : 929 - 934
  • [39] Comparative Pharmacodynamic Assessment of the Antiangiogenesis Activity of Heparin and Low-Molecular-Weight Heparin Fractions: Structure-Function Relationship
    Mousa, Shaker A.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (01) : 48 - 54
  • [40] PLASMA LIPOLYTIC-ACTIVITY AND SUBSTRATE OXIDATION AFTER INTRAVENOUS ADMINISTRATION OF HEPARIN AND A LOW-MOLECULAR-WEIGHT HEPARIN FRAGMENT
    PERSSON, E
    NORDENSTROM, J
    NILSSONEHLE, P
    HAGENFELDT, L
    WAHREN, J
    [J]. CLINICAL PHYSIOLOGY, 1990, 10 (06): : 573 - 583